Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PTGES | O14684 | 3/20 | 0.45 |
| ▸ | BRS3 | P32247 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8470973 | 0.86 | FOLH1 (0.50) | FOLH1TSHRALDH1A1PTGESALOX15 | |
| SCHEMBL8470980 | 0.86 | FOLH1 (0.50) | FOLH1TSHRALDH1A1PTGESALOX15 | |
| SCHEMBL8447505 | 0.84 | FOLH1 (0.49) | FOLH1TSHRALDH1A1PTGESALOX15 | |
| SCHEMBL27983622 | 0.83 | SCN1A (0.53) | FOLH1ALDH1A1HTR2AHTR2C | |
| SCHEMBL28056103 | 0.83 | PPM1D (0.44) | FOLH1TSHRALDH1A1BRS3KMT2A | |
| SCHEMBL8727358 | 0.82 | FOLH1 (0.46) | FOLH1TSHRALDH1A1PTGESBRS3 | |
| SCHEMBL8727361 | 0.82 | FOLH1 (0.46) | FOLH1TSHRALDH1A1PTGESBRS3 | |
| SCHEMBL28569359 | 0.82 | FOLH1 (0.53) | FOLH1TSHRALDH1A1ALOX15GRIK1 | |
| SCHEMBL6175349 | 0.81 | TP53 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL28056027 | 0.80 | PPM1D (0.47) | BRS3KMT2AACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9920038-B2 | Methyl oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170260177-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355692-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | FOLH1 2332/4885TSHR 283/4885ALDH1A1 2102/4885 |
| US-20170260177-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | FOLH1 1820/4885TSHR 305/4885ALDH1A1 2804/4885 |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | FOLH1 1097/4885TSHR 372/4885ALDH1A1 2028/4885 |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | FOLH1 1828/4885TSHR 272/4885ALDH1A1 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.